DeepMed Research

Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

Intraperitoneal Injection of Oncolytic Viruses H101 for Patients With Refractory Malignant Ascites

Phase 2

Completed

Conditions: Refractory Malignant Ascites

Interventions: Drug: Oncorine (H101)

First Posted Date: 2021-02-25

Last Posted Date: 2023-01-31

Lead Sponsor: Fudan University

Target Recruit Count: 25

Registration Number: NCT04771676

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Dynamic Observational Study With PET of 68Ga-HER2-affibody in Anti-HER2 Treatment

Conditions: Breast Cancer

Interventions: Drug: Docetaxel combined with Trastuzumab±Pertuzumab
Drug: T-DM1 or Capecitabine combined with Pyrotinib regimen.

First Posted Date: 2021-02-24

Last Posted Date: 2022-04-20

Lead Sponsor: Fudan University

Target Recruit Count: 50

Registration Number: NCT04769050

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

SBRT for Oligo-residual NSCLC After Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors

Phase 2

Recruiting

Conditions: NSCLC Stage IV

Interventions: Drug: PD-1/PD-L1 inhibitors (alone or in combination with chemotherapy)
Radiation: SBRT

First Posted Date: 2021-02-23

Last Posted Date: 2025-04-30

Lead Sponsor: Fudan University

Target Recruit Count: 59

Registration Number: NCT04767009

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Observational Prospective Study of Immune Checkpoint Inhibitors for Solid Neoplasms

Recruiting

Conditions: Cancer

First Posted Date: 2021-02-23

Last Posted Date: 2021-02-23

Lead Sponsor: Fudan University

Target Recruit Count: 1500

Registration Number: NCT04766515

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs

Phase 2

Completed

Conditions: EGFR Activating Mutation
NSCLC Stage IV

Interventions: Drug: 3rd generation EGFR-TKI
Radiation: Consolidative SRT

First Posted Date: 2021-02-21

Last Posted Date: 2024-08-19

Lead Sponsor: Fudan University

Target Recruit Count: 61

Registration Number: NCT04764214

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17)

Phase 2

Active, not recruiting

Conditions: Esophagus Cancer
Chemoradiotherapy
Radiation Therapy
Esophageal Squamous Cell Carcinoma
Postoperative

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Radiation: Radiotherapy

First Posted Date: 2021-02-21

Last Posted Date: 2023-08-03

Lead Sponsor: Fudan University

Target Recruit Count: 70

Registration Number: NCT04764227

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Raltitrexed in HIPEC

Phase 1

Conditions: Colorectal Cancer
HIPEC
Raltitrexed

Interventions: Drug: Raltitrexed

First Posted Date: 2021-02-18

Last Posted Date: 2021-02-18

Lead Sponsor: Fudan University

Target Recruit Count: 15

Registration Number: NCT04761185

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Study on the Value of Non-invasive Dual-Pet Information in Subtype of Metastatic Breast Cancer

Conditions: Breast Cancer

Interventions: Procedure: biopsy or surgical pathology in metastases
Drug: 68Ga-HER2 affibody,18F-FDG, 18F-FES

First Posted Date: 2021-02-17

Last Posted Date: 2022-04-20

Lead Sponsor: Fudan University

Target Recruit Count: 50

Registration Number: NCT04758416

Locations: 🇨🇳
Shanghai Cancer Center Institutional Review Board, Shanghai, Shanghai, China

Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer

Phase 2

Conditions: Triple Negative Breast Cancer

Interventions: Drug: Personalized treatment guided by mini-PDX and RNA sequencing
Drug: Nab paclitaxel
Drug: Eribulin
Drug: Vinorelbine
Drug: Gemcitabine
Drug: Capecitabine

First Posted Date: 2021-02-09

Last Posted Date: 2022-04-20

Lead Sponsor: Fudan University

Target Recruit Count: 100

Registration Number: NCT04745975

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Study on Pulmonary Rehabilitation for Stable Chronic Obstructive Pulmonary Disease(COPD) Patients

Not Applicable

Conditions: Muscle Strength
Respiratory Function Tests
Nutritional Support
Aerobic Exercise
Body Composition

Interventions: Behavioral: rehabilitation exercise
Dietary Supplement: oral nutritional supplements
Other: health education

First Posted Date: 2021-02-05

Last Posted Date: 2021-04-13

Lead Sponsor: Fudan University

Target Recruit Count: 90

Registration Number: NCT04741373

Locations: 🇨🇳
Huadong Hospital Affiliated to Fudan University, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy